Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    24-September-2000      
Issue 164 Next Update - 14:00 UTC 08:00 EST    25-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya MVA Vaccine For AIDS Cleared For Human Testing

IAVI-Sponsored Vaccine Is Designed Specifically For Africa

An AIDS vaccine candidate designed specifically for Africa and manufactured in Germany has been approved for human testing. Wayne Koff Ph.D., Vice President for Research and Development of the International AIDS Vaccine Initiative (IAVI), has announced that the Medicines Control Agency (MCA) of the United Kingdom has approved Phase I testing of an MVA vaccine based on HIV subtype A, the most common strain in Kenya and in many other parts of Africa.

The MVA, or modified vaccinia Ankara-strain, vaccine was designed by Dr. Thomas Hanke at the Medical Research Council Human Immunology Unit in Oxford and manufactured under contract by Impfstoffwerke Dessau-Tornau, GmbH (IDT), a pharmaceutical company in Rosslau, Germany. "Producing the required amounts of high-quality vaccine for this study is a relatively small contribution to the solution of the AIDS-problem," says Heinz Hofmann, executive manager of IDT. "A vaccine for Africa developed through advanced technology in Europe could, however, be a decisive step forward."

The MVA vaccine is the second component of a novel prime-boost vaccination strategy. The first component, a DNA vaccine, entered Phase I trials in Oxford, England at the end of August. Pending approvals from the appropriate Kenyan authorities it is hoped that the DNA vaccine will move into human trials in Nairobi, Kenya within the next six months. The German-manufactured MVA vaccine will first be tested in Oxford and then in Nairobi and then the two components will be tested as a combination in Oxford and in Nairobi.

Both vaccine candidates are the product of a partnership between the research teams of Professor Andrew McMichael of the Medical Research Council Human Immunology Unit at Oxford University in the United Kingdom and Professor J.J. Bwayo of the University of Nairobi in Kenya. The Oxford/Nairobi Partnership is the first of four vaccine development partnerships funded by the International AIDS Vaccine Initiative (IAVI), a global scientific organization dedicated to accelerating the development of AIDS vaccines for use throughout the world.

According to Professor McMichael, "Preclinical studies with the combination of DNA + MVA validated the strategy that by combining the two vaccines, immune responses against the virus are optimized, compared with vaccinating with either DNA or MVA alone. These studies provided the rationale for IAVI's decision to fast-track both candidate vaccines into clinical trials."

The rationale for this approach comes from extensive studies of sex workers in Nairobi. Despite continuous exposure to HIV, a small minority of these women has resisted infection over many years. "We hope this vaccine will stimulate the same strong cellular immune response to HIV that we have seen in these women," said Prof. Bwayo, who is chairman of the Department of Medical Microbiology at the University of Nairobi.

Bwayo said, "Until now, most AIDS vaccines have been made from strains circulating in the North, specifically, subtype B. The development of this vaccine begins to address the great need for vaccines designed specifically for Africa." He added: "We recognize that vaccine trials on HIV/AIDS present unique challenges. Any vaccine trials on humans must go through rigorous safety and ethical protocols. With HIV we are insisting on even higher standards of safety and ethics. The proposed vaccine is not curative but preventive. It is inspired by findings by our scientists in Nairobi."


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.